(2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,14R,17S)-14,17-dihydroxy-4-methyl(13,14,15,15-2H4)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

• ChemBase编号: 171027
• 分子式: C23H29NO10
• 平均质量: 479.47706
• 单一同位素质量: 479.17914613
• SMILES: c1(c2c3c(cc1)C[C@@H]1[C@]4([C@@]3([C@H]([C@@H](CC4)O)O2)CCN1C)O)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)C(=O)O)O)O)O
• Canonical SMILES: O[C@@H]1[C@H](O)[C@@H](O[C@H]([C@H]1O)C(=O)O)Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)CC[C@H]1O)C
• InChI: InChI=1S/C23H29NO10/c1-24-7-6-22-13-9-2-3-11(32-21-16(28)14(26)15(27)18(34-21)20(29)30)17(13)33-19(22)10(25)4-5-23(22,31)12(24)8-9/h2-3,10,12,14-16,18-19,21,25-28,31H,4-8H2,1H3,(H,29,30)/t10-,12-,14+,15+,16-,18+,19?,21-,22+,23-/m1/s1
• InChIKey: IJMSQWNXMRYVBK-ZDLGVZNDSA-N

名称和登记号

名称

• IUPAC标准名: (2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,14R,17S)-14,17-dihydroxy-4-methyl(13,14,15,15-^2H₄)-12-oxa-4-azapentacyclo[9.6.1.0^1,^1^3.0^5,^1^7.0^7,^1^8]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• IUPAC传统名: (2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,14R,17S)-14,17-dihydroxy-4-methyl(13,14,15,15-^2H₄)-12-oxa-4-azapentacyclo[9.6.1.0^1,^1^3.0^5,^1^7.0^7,^1^8]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• 别名: 6β-Hydroxy Oxymorphone-d4 β-D-Glucuronide

登记号

• PubChem SID: 164226937
• PubChem CID: 71749228

理论计算性质

• Acid pKa: 2.6639864
• 质子受体: 11
• 质子供体: 6
• LogD (pH = 5.5): -4.201557
• LogD (pH = 7.4): -4.212203
• Log P: -4.201511
• 摩尔折射率: 112.4687 cm^3
• 极化性: 45.27582 Å^3
• 极化表面积: 169.38 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: false

详细说明

Toronto Research Chemicals - H948887

A labelled metabolite of Oxymorphone.

参考文献

• Christensen, C.B., et al.: Pharmacol. Toxicol., 60, 75 (1987)
• Osborne, R., et al.: Clin. Pharmacol. Ther., 47, 12 (1987)
• Carrupt, P.A., et al.: J. Med. Chem., 34, 1272 (1987)